Skip to content

Comparison of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and conventional facemask ventilation during electroconvulsive therapy

Comparison of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and conventional facemask ventilation during electroconvulsive therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084318
Enrollment
Unknown
Registered
2024-05-14
Start date
2024-06-04
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder, schizophrenia, and major depressive disorder

Interventions

THRIVE group:The Optiflow THRIVE (Fisher & Paykel Healthcare, Auckland, New Zealand) is a humidifier with an integrated flow generator that delivers high-flow, warmed, and humidified oxygen at up to 7
Facemask group:In the facemask group, preoxygenation with 100% oxygen was carried out for 3 minutes at a rate of 10 L/min, with no positive airway pressure applied, using an appropriately sized mask.

Sponsors

The Affiliated Brain Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) adult psychiatric patients (aged 18–65 years) who had been diagnosed with schizophrenia, BD, or MDD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V); (2) patients with American Society of Anesthesiologists (ASA) physical status I-II; (3) patients with a BMI between 18.5 and 23.9 kg/m2 due to the risk of desaturation associated with a higher BMI; (4) patients who were able to receive THRIVE technique following instructions properly.

Exclusion criteria

Exclusion criteria: (1) the presence of other psychiatric disorders as defined by DSM-IV, such as alcohol or substance use disorder; (2) those suffering from obstructive sleep apnea syndrome (OSAS) along with nasopharyngeal abnormalities, epistaxis, or a history of nasal surgery; (3) known or anticipated airway obstruction requiring intubation; (4) patients suffering from severe or unstable somatic conditions, such as chronic obstructive pulmonary disease (COPD) or emphysema; (5) pregnant or nursing women; (6) contraindications to ECT or anesthesia.

Design outcomes

Primary

MeasureTime frame
The lowest SpO2 levels;

Secondary

MeasureTime frame
The incidence of oxygen desaturation;EEG seizure duration;stimulation dosage;vital signs (including average SpO2 levels, HR, and MAP);

Countries

China

Contacts

Public ContactSha Nie

The Affiliated Brain Hospital of Guangzhou Medical University

niesa002@163.com+86 189 2216 5281

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026